# Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

> **NCT01873157** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 44 (actual)

## Conditions studied

- Late Rejection of Renal Transplant
- Antibody-mediated Rejection

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01873157
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-02
- **Final completion:** 2017-02-28
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873157, "Bortezomib in Late Antibody-mediated Kidney Transplant Rejection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01873157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*